Supporting Information

Near-infrared light-controlled, oxygen-independent radical generating nano-system toward cancer therapy

Desheng Cao^{a,#}, Hua He^{a,#}, Wei Li^a, Jin Yan^a, Jianhua Wu^{b,*}, Mengyuan Yin^a, Yang Zhou^a, Zhuchao Zhou^{b,*}, Lichen Yin^{a,*}

^a Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Institute of Functional Nano and Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou 215123, China

^b Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China

[#] Cao D and He H contributed equally.

Email: <u>lcyin@suda.edu.cn</u> (Yin L), <u>zhouzhuchao@hotmail.com</u> (Zhou Z), <u>wujianhua1588@gmail.com</u> (Wu J.)



Fig. S1. TEM image of PB NPs. Scale bar = 100 nm.



Fig. S2. Size distributions of PB NPs (A) and HPB NPs (B).



Fig. S3. Zeta potentials of PB NPs, HPB NPs, and AP@HPB NPs (n = 3).



Fig. S4. BET analysis of HPB NPs. Nitrogen adsorption-desorption isotherm (A) and pore size distribution (B) of HPB NPs.



Fig. S5. UV-Vis absorbance spectra of AIBI at various concentrations.



Fig. S6. UV-Vis absorbance spectra of HPB NPs and AP@HPB NPs.



Fig. S7. CLSM images of 4T1 cells incubated with FP@HPB NPs (40 μ g/mL) for different time. Cell nuclei were stained with Hoechst. Scale bar = 100 μ m.



Fig. S8. Uptake levels of FP@HPB NPs (40 μ g/mL) in 4T1 cells following incubation at 37 °C for different time (n = 3).



Fig. S9. Viability of 4T1 (A), HeLa (B), and LLC (C) cells following 6-h incubation with AIBI, HPB NPs, or AP@HPB NPs (n = 3).



Fig. S10. Cytotoxicity of AIBI, HPB NPs, and AP@HPB NPs to HeLa (A) and LLC (B) cells with laser irradiation (808 nm, 0.8 W/cm^2 , 5 min) under normoxic condition (n = 3).



Fig. S11. Cytotoxicity of AP@HPB NPs to HeLa (A) and LLC (B) cells with laser irradiation (808 nm, 0.8 W/cm^2 , 5 min) under normoxic and hypoxic conditions (n = 3).

II III IV

I



Fig. S12. Images of 4T1 tumor-bearing mice on day 14 in the *in vivo* efficacy study. Each group represents (I) PBS + (L), (II) AIBI + (L), (III) HPB NPs (+L), and (IV) AP@HPB NPs (+L).



Fig. S13. H&E-stained major organ sections harvested on day 14 in the *in vivo* efficacy study. Scale bar = $100 \mu m$.